Global Retirement Partners LLC Sells 147 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Global Retirement Partners LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 484 shares of the biopharmaceutical company’s stock after selling 147 shares during the period. Global Retirement Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $345,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in REGN. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. Fairfield Financial Advisors LTD bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $37,000. Private Wealth Management Group LLC boosted its stake in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 39 shares in the last quarter. Finally, Truvestments Capital LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at $39,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $713.25 on Tuesday. The business’s fifty day moving average is $699.17 and its 200-day moving average is $878.35. The company has a market cap of $77.98 billion, a P/E ratio of 18.63, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $11.86 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.49%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

Analyst Ratings Changes

A number of brokerages have issued reports on REGN. Citigroup cut their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Finally, Bernstein Bank decreased their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.